scholarly journals Significance of posterior acoustic enhancement ultrasonographic findings in the diagnosis of hepatocellular carcinoma

2019 ◽  
Vol 72 (5-6) ◽  
pp. 160-164
Author(s):  
Jelena Stosic ◽  
Srdjan Stosic ◽  
Biljana Kukic ◽  
Mladjan Protic
Keyword(s):  
Hepatocellular Carcinoma ◽  
Retrospective Study ◽  
Liver Disease ◽  
Ultrasound Examination ◽  
Significant Finding ◽  
Focal Lesions ◽  
Hepatocellular Carcinomas ◽  
Focal Hepatic Lesions ◽  
Patients At Risk ◽  
Hepatic Lesions

Introduction. On ultrasound, hepatocellular carcinoma presents with nodular or multinodular lesions of different size and echostructure, sometimes with a surrounding halo, and lateral acoustic shadows or posterior acoustic enhancement. The aim of this study was to determine the incidence of posterior acoustic enhancement in hepatocellular carcinoma. Material and Methods. This retrospective study included 120 patients with pathologically verified hepatocellular carcinoma who had undergone ultrasound examination (using real time ultrasounds from different manufacturers, with 3.5 and 5 MHz probes). Ultrasound imaging focused on the size and appearance of the focal lesions, i. e. echostructure and presence or absence of posterior acoustic enhancement as areas of increased echogenicity behind the lesion. Results. Posterior acoustic enhancement was observed in 47.3% of all nodular hepatocellular carcinomas, whereas this ultrasound phenomenon was statistically significantly more common in the group of tumors from 3 to 5 cm in size. In the group of multinodular tumors, posterior acoustic enhancement was found in 70% of cases. Conclusion. The presence of posterior acoustic enhancement in the detection of focal hepatic lesions may be a significant finding in the diagnosis of hepatocellular carcinoma, especially in patients at risk for developing hepatocellular carcinoma (cirrhosis and chronic liver disease), as well as in monitoring interval growth in size of focal lesions using this ultrasound phenomenon.

scholarly journals Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease

2015 ◽  
Vol 13 (2) ◽  
pp. 326-329
Author(s):  
Marcio Augusto Correia Rodrigues dos Reis ◽  
Ronaldo Hueb Baroni
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Contrast Medium ◽  
Chronic Liver Disease ◽  
Hepatic Function ◽  
Chronic Liver ◽  
Hepatobiliary Phase ◽  
Hepatocellular Carcinomas ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions

ABSTRACT The hepatobiliary-specific contrast medium (gadoxetic acid – Primovist®) is primarily used to improve detection and characterization of focal hepatic lesions, such as in chronic liver disease patients with suspected hepatocellular carcinoma. Since the contrast medium is selectively taken up by functioning hepatocytes in the late hepatobiliary phase, it helps to detect typical hepatocellular carcinoma, which show low signal intensity on this phase. This imaging feature also assists in differentiating regenerative/dysplastic nodules from early hepatocellular carcinomas (with over 90% accuracy), as well as hypervascular hepatocellular carcinomas from arterial pseudo-enhancement foci. Future perspectives include its use in quantification of hepatic function and fibrosis.

Ascitic Fluid Cytokines in Chronic Liver Disease: A Possible Prognostic Tool

2021 ◽  
Author(s):  
Shimaa atta ◽  
Manal Kamel ◽  
Wafaa Mansour ◽  
Taghreed Hussein ◽  
Kesmat Maher ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Ascitic Fluid ◽  
Serum Levels ◽  
Malignant Ascites ◽  
Focal Lesions ◽  
Prognostic Tool ◽  
Significant Difference ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions ◽  
Fluid Levels

Introduction: Malignant ascites results from imbalance between protein in the peritoneal cavity and absorption of fluids via the lymphatic system. More than twenty interleukins are known to play an important role in the protection against tumors. Materials and methods: Ascitic fluid IL1B, IL2, IL4, IL6, IL10, TNFα, and IFNγ levels were assessed in forty-five patients with liver cirrhosis and ascites as judged by histopathological and ultra-sonographic findings. They were divided into two groups according to presence of hepatic focal lesions. Ten patients with focal hepatic lesions were randomly selected and subjected to analysis of serum levels of IL2 and IL10. Results: Ascitic fluid IL-4, IL-6 and IL-10 levels were found to be significantly higher in patients with hepatocellular carcinoma than patients with cirrhosis. TNFα, and IFNγ were also found to be higher in hepatocellular carcinoma than patients with cirrhosis but with no significance. On the other hand, there was no significant difference in levels of IL1B and IL2 between the two groups. Ascitic fluid IL2 and IL10 levels were found to be higher in ascitic fluid than in serum of the same patients. Conclusion: Ascitic fluid levels of IL-4, IL-6 and IL-10 are higher in hepatocellular carcinoma patients than patients with cirrhosis alone. Levels of ascitic fluid IL2 and IL10 were proved to be a better prognostic tool than their levels in sera of the same patients. To conclude; patients with cirrhosis may be subjected to schedualed examination of ascitic fluid cytokine to predect transformation into hepatocellular carcinoma.

Role of MRI in Detecting and Characterizing Small Hepatic Focal Lesions

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Rania Ali Maarouf ◽  
Ali Haggag Ali ◽  
Mahmoud Abdelatif Onsy
Keyword(s):  
Tumor Staging ◽  
Left Lobe ◽  
Diagnostic Process ◽  
Liver Imaging ◽  
Focal Lesions ◽  
Focal Hepatic Lesions ◽  
Malignant Lesions ◽  
Hepatic Lesions ◽  
The Right

Abstract Background Despite the recent advances in liver imaging, the detection and characterization of small hepatic focal lesions is still a real challenge. Particularly in cancer patients where the characterization of a small HFL as thus the precise tumor staging is critical for optimal treatment planning. Aim of the Work To explore the effectiveness, and hence the clinical utility, of MRI detection and characterization of small focal hepatic lesions either only discovered on MRI or as a further work up of CT/US-indeterminate lesions. Patients and Methods We reviewed our database for individuals who underwent liver MR imaging between March 2018 and March 2019 for the evaluation of small hepatic lesions that were discovered for the first time or had been previously visualized on routinely performed CT and had been considered indeterminate. Results The present study included 44 patients of which 26 were males (59.1%) and 18 were females (40.9%). The age range of the study group was 19 to 77 years. The mean age for Malignant lesions was 51 years. The right lobe of liver was involved in 23 cases (52.3%), left lobe in 5 cases (11.4%) and both lobes in 16 cases (36.4%). There were 30 (68.18%) benign, 13 (29.54%) malignant lesions and 1 (2.3%) indeterminate, hemangiomas were predominant in benign lesions whereas hepatocellular carcinomas were predominant in malignant lesions. N'TRI could characterize 92% cases. Conclusion The diagnostic process of small hepatic focal lesions, either detection or characterization or both, continues to represent a challenge. Contrast-enhanced MR can accurately detect and characterize majority of small hepatic focal lesions.

Malignant Transformation Arising Within Unusual and Rare Hepatic Lesions: Fibropolycystic Disease Form of Ductal Plate Malformation and Biliary Adenofibroma

2018 ◽  
Vol 26 (6) ◽  
pp. 542-550 ◽  
Author(s):  
Darren Chua ◽  
Adrian Kah Heng Chiow ◽  
Tiing Leong Ang ◽  
Lai Mun Wang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Malignant Transformation ◽  
Intrahepatic Cholangiocarcinoma ◽  
Ductal Plate ◽  
Hepatobiliary Cancer ◽  
Ductal Plate Malformation ◽  
Biliary Adenofibroma ◽  
Hepatic Lesions

Cholangiocarcinoma is the second most common hepatobiliary cancer following hepatocellular carcinoma, and 20% to 25% are intrahepatic. We describe 2 cases of intrahepatic cholangiocarcinoma arising within unusual and rare hepatic lesions, fibropolycystic liver disease form of ductal plate malformation and biliary adenofibroma, whose association with malignancy is rarely reported in the literature.

Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions

2013 ◽  
Vol 99 (1) ◽  
pp. 100-107 ◽  
Author(s):  
Ashraf Khalil ◽  
Jamalat Elgedawy ◽  
Mohammed F Faramawi ◽  
Ashraf Elfert ◽  
Ibrahim Salama ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Malignant Tumors ◽  
Treatment Options ◽  
Alpha Fetoprotein ◽  
Egyptian Patients ◽  
Diagnostic Role ◽  
Focal Hepatic Lesions ◽  
Serum Alpha Fetoprotein ◽  
Hepatic Lesions

Aims Hepatocellular carcinoma is one of the most aggressive malignant tumors and has limited treatment options. Needle-guided biopsies have been utilized as a tool to diagnose malignant focal hepatic lesions. These techniques are discouraged because of their complications. Nowadays, alpha fetoprotein is the most widely used tumor marker for screening and diagnosis of hepatocellular carcinoma. Nevertheless, this marker has limitations. The diagnostic role of plasma osteopontin as an adjuvant or alternative marker to alpha fetoprotein to detect hepatocellular carcinoma in Egyptian patients with focal hepatic lesions was evaluated in this study. Subject and methods Eighty participants were recruited from the Egyptian National Liver Institute and were self-assigned to three groups, namely, focal hepatic lesions (n = 40), liver cirrhosis (n = 20), and controls (n = 20). Participants' plasma osteopontin and serum alpha fetoprotein levels were determined and were compared across the three groups. Results The discriminatory ability of plasma osteopontin for hepatocellular carcinoma was lower than that of alpha fetoprotein. Osteopontin and alpha fetoprotein were not correlated with each other. Neither the gender nor the age of the patients showed a significant association with plasma osteopontin level. Conclusion Measuring plasma osteopontin level alone has no advantage over serum alpha fetoprotein in patients with focal hepatic lesions due to chronic liver disease.

Abdominal Ultrasonography in Myelofibrosis

1992 ◽  
Vol 33 (4) ◽  
pp. 343-346 ◽  
Author(s):  
T. M. J. Siniluoto ◽  
S. A. Hyvärinen ◽  
M. J. Päivänsalo ◽  
M. J. Alavaikko ◽  
I. J. I. Suramo
Keyword(s):  
Fine Needle Biopsy ◽  
Extramedullary Hematopoiesis ◽  
Primary Diagnosis ◽  
Definitive Diagnosis ◽  
Initial Diagnosis ◽  
Focal Lesions ◽  
Abdominal Ultrasonography ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions ◽  
Focal Splenic Lesions

The findings at abdominal ultrasonography (US) in 40 patients with myelofibrosis were reviewed, 20 patients being examined at initial diagnosis and 31 at later stages. Splenomegaly was found in 80% at initial diagnosis and in 97% at later stages. The spleen of 2 patients appeared homogeneously hypoechoic and inhomogeneous in one. Focal splenic lesions were seen in 5, and calcifications in 6. Mixed splenic lesions proved to be metastases in one and hyperechoic lesions in another patient were due to extramedullary hematopoiesis. Hepatomegaly was found in 25% at primary diagnosis and in 39% at later stages. Focal hepatic lesions were seen in 7 patients, and proved to be metastases in 3. The focal lesions in 2 of these patients were extramedullary hematopoiesis, which was hypoechoic in one and hyperechoic in the other. Ascites was seen in 4 patients and lymphadenopathy in one. US could not reliably differentiate between extramedullary hematopoiesis and malignancy. Fine-needle biopsy may be performed for definitive diagnosis.

scholarly journals Inadequate Ultrasound Examination in Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (16) ◽  
pp. 3535
Author(s):  
Seung Baek Hong ◽  
Dong Hwan Kim ◽  
Sang Hyun Choi ◽  
So Yeon Kim ◽  
Ji Sung Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Ultrasound Examination ◽  
Meta Analysis ◽  
Significant Risk ◽  
High Body Mass Index ◽  
Random Effects Model ◽  
Cochrane Database ◽  
Patients At Risk ◽  
Hepatocellular Carcinoma Surveillance

We aimed to systematically evaluate the incidence of inadequate US in hepatocellular carcinoma (HCC) surveillance and determine the risk factors. Original studies reporting the incidence or risk factors for inadequate US were identified in MEDLINE, EMBASE, and the Cochrane database. The pooled incidence of inadequate US was calculated using a random effects model, and subgroup analyses were performed. The pooled odds ratio (OR) was calculated for each risk factor for inadequate US. Six eligible articles were identified from 756 screened articles (4250 patients). The pooled incidence of inadequate US was 21.5%. Significantly higher rates of inadequate US were noted in studies including patients with and without hepatic observations compared with those evaluating only patients with hepatic observations (23.2% vs. 18.8%), studies using US alone compared with US plus alpha-fetoprotein (28.0% vs. 20.8%), and those using pathology and imaging as a reference standard compared with imaging only (23.2% vs. 17.9%). Nonalcoholic steatohepatitis (OR = 2.3 (1.07–4.84)), Child–Pugh B cirrhosis (OR = 2.2 (1.10–4.37)), and high body mass index (OR = 2.2 (1.12–4.24)) were significant risk factors for inadequate US (p ≤ 0.04). In patients at risk of HCC, 21.5% of US surveillance was inadequate. An alternative surveillance modality might be considered in patients with risk factors.

Sign in / Sign up

Export Citation Format

Share Document